ASX RELEASE.

emyria
Advanced Therapies | Compassionate Care

For personal use only

25 November 2026

GLOBAL PSYCHEDELIC LEADER COMPASS PATHWAYS SELECTS EMYRIA FOR CLINICAL TRIAL

Empax Global Partnership Program Expands as second Drug Sponsor selects Emyria, strengthening its growing pharmaceutical-sponsored clinical trials business.

- **SELECTED AS A SITE IN A GLOBAL PSILOCYBIN TRIAL:** Compass Pathways (**NASDAQ: CMPS)**, is advancing what it describes as the world's largest classic psychedelic clinical program[1] and has selected Emyria's Empax Centre as a site for its global Phase 2b/3 COMP202 trial evaluating investigational COMP360 psilocybin treatment for post-traumatic stress disorder (PTSD)[2].
- **SIGNIFICANT REVENUE OPPORTUNITY:** Estimated revenue of **~A$1.5m** based on conservative recruitment numbers of 20 participants. Revenue could be higher if further recruitment is achieved. Actual revenue will be based on final recruitment numbers and completed study activities.
- **FURTHER COMMERCIAL PROGRESS FOR EMPAX GLOBAL PARTNERSHIP PROGRAM (EGPP):** Compass is the latest international drug developer[3] to select Emyria's Empax network. This strengthens Emyria's dual business model of sponsor-funded trial activities and reimbursed treatment programs.
- **LEVERAGING EXISTING INFRASTRUCTURE:** Drug-sponsored trials leverage Emyria's established specialist facilities, trained workforce and regulatory capabilities, creating opportunities for increased revenue, higher facility utilisation and greater operating margins.

Emyria Limited (ASX: EMD) ("Emyria", or the "Company"), a leader in delivering evidence-based intensive mental healthcare, is pleased to announce that **Compass Pathways plc (Nasdaq: CMPS)** has selected its Empax Centre in Leederville, Western Australia, as a site for its global Phase 2b/3 COMP202 Redefine Study. The Redefine Study is a large international trial that aims to enrol approximately 300 adults with PTSD.[1]

The trial will evaluate the efficacy, safety, and tolerability of COMP360, Compass Pathways' proprietary investigational synthetic psilocybin treatment, in adults with PTSD.

Incremental revenue for the Company is estimated at **~$1.5m** based on a conservative recruitment target of 20 participants completing the study activities. Whilst this will deliver a substantive increase in annual revenue in its own right (FY26 revenue was approximately A$4.05 million), the agreement provides for a target number of patients recruited of up to 32 participants, and additional participants may be recruited under the study's competitive recruitment framework. Given Emyria's warm pipeline of potential patients, selection in this trial represents a significant revenue opportunity for the Company. Emyria's established

referral pathways and significant PTSD patient enquiries provide a solid foundation to support recruitment, subject to study-specific eligibility requirements.

The parties have entered into a standard form clinical trial agreement. Emyria will be responsible for conducting clinical trial activities, including screening eligible participants, preparation and follow-up sessions before and after a participant is dosed, monitoring during each dosing session, safety and efficacy assessments, and data entry.

Patient recruitment is targeted to commence in December 2026, subject to HREC approval and site activation.

EMYRIA'S CLINICAL PLATFORM IS BUILT FOR TRIALS OF THIS KIND

Compass selected Emyria after a feasibility assessment and site qualification process. This included a visit by the Sponsor to Emyria's Empax Centre in Leederville, Western Australia.

Emyria specialises in interventional psychiatry including psychological trauma care. The Company has established a national network of Empax Centres comprising multidisciplinary teams of psychiatrists, psychologists and therapists that treat various patient cohorts with PTSD and treatment-resistant depression.

SPONSOR-FUNDED TRIALS BUILD A REPEATABLE REVENUE STREAM

Emyria's selection as a trial site is indicative of growing interest from international drug developers in the Company's clinical platform, strengthening Emyria's dual business model of sponsor-funded trial activities and reimbursed treatment programs.

Launched in April 2026[3], this opportunity represents further commercial progress for Emyria's Empax Global Partnership Program which aims to provide international drug developers with access to its specialist facilities, trained workforce, and regulatory capabilities.

Importantly, Emyria can deliver these services through infrastructure already established to treat real-world patients, generating additional incremental revenue opportunities from existing facilities and personnel.

By leveraging its existing clinical infrastructure, Emyria is positioned to pursue additional drug-sponsored revenue, creating opportunities for higher facility utilisation, improved operating margins, and a scalable clinical trials services business alongside its reimbursed treatment programs.

ABOUT COMPASS PATHWAYS

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Compass' initial focus is in developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 is a potentially first-in-class treatment and has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), as well as Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. Compass is leading the world's largest classic psychedelic clinical program in TRD, and building upon that robust foundation, Compass is executing a late-stage trial evaluating COMP360 for PTSD, another condition with

For personal use only

high unmet need. Compass' goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability with infrequent dosing.

Compass is headquartered in London, UK, with a U.S. office in New Jersey.

NEXT STEPS

Emyria will progress HREC approval and site activation, targeting patient recruitment from December 2026 subject to necessary approvals.

The Company will continue delivering reimbursed treatment programs while pursuing additional international drug sponsor partnerships through its Empax Global Partnership Program.

Executive Chair Greg Hutchinson commented:

"We are excited to be selected as a trial site by one of the world's leading psychedelic drug developers. We share Compass's focus on people suffering with PTSD who have not found relief from existing treatments and are proud to give Australian patients access to this important study.

Our specialist infrastructure, trained workforce and experience treating real world patients within regulated healthcare settings are proving attractive to international drug sponsors.

Being selected to participate in this trial is indicative of that and an important commercial milestone. We look forward to working closely with the Compass team on this study."

COMP202 Redefine Study details:

ITEM	DESCRIPTION
Protocol Title	A Phase 2b/3, multicentre, randomised, double-blind, controlled trial, with an open-label extension, to investigate the efficacy, safety, and tolerability of COMP360 in participants with post-traumatic stress disorder (the Redefine Study, COMP202)
Sponsor	Compass Pathways plc (Nasdaq: CMPS), through its affiliate Compass Pathfinder Limited
Trial Registration	ClinicalTrials.gov NCT07570654[1]
Development Phase	Phase 2b/3
Primary Endpoint	Change in PTSD symptom severity from Baseline to Week 8, measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity score, for COMP360 25 mg compared with COMP360 1 mg
Trial Summary	The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.

For personal use only

ITEM	DESCRIPTION
Number of Trial Subjects & Selection Criteria	Approximately 300 participants across all sites. Participants will be adults (aged 18 years or older) with a diagnosis of PTSD for at least 6 months. People with certain psychiatric conditions, such as bipolar disorder, schizophrenia, obsessive-compulsive disorder or anorexia nervosa, are not eligible.
Trial Standard	The study is conducted in accordance with international best practice standards and the principles of Good Clinical Practice (GCP), as outlined by the International Council for Harmonisation (ICH).

References:

1. https://www.compasspathways.com/our-work
2. https://www.allclinicaltrials.com/study/NCT07570654
3. See ASX release 20 April 2026

This release has been approved by the Board of Emyria.

For further information, investment opportunities, or more about Emyria's approach to mental health treatment, please contact:

Greg Hutchinson Executive Chair
1300 153 355 | investors@emyria.com

For personal use only

Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:



Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.

Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

For personal use only

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.